| Literature DB >> 31143372 |
Xiaoman Chen1, Yulu Shi2, Kaiwen Zhou1, Sijie Yu2, Wei Cai3, Muying Ying1.
Abstract
The global outputs of annual publication in long non-coding RNAs (lncRNAs) and chemotherapeutic resistance research exponentially increased from 2 in 2008 to 176 in 2017. Using Java application CiteSpace V and VOSviewer, this study assessed the publication model of lncRNAs and chemoresistance by bibliometric analysis. Totally, 2883 authors contributed 528 publications of lncRNAs and chemoresistance in 215 academic journals in the recent decade (2008-2018). Oncotarget in the 215 academic journals published the highest number of publications (60). China had the highest number of publication outputs (358). The leading institute was Nanjing Medical University. Wang Y was the most influential author (13 counts). Gupta RA had the most cited documents (87 counts). "Gene expression" and "poor prognosis" were identified as the hotspots. "Cancer stem cell", "HOTAIR" and "UCA1" were the frontiers of the fields in recent years. The increase of publications on lncRNAs and chemotherapeutic resistance will continue in the next years. HOTAIR and UCA1 with multiple roles in drug resistance may offer big opportunities for targeted chemoresistance in cancer therapy. These results may help us discover and explain the possible underlying laws of the subject.Entities:
Keywords: bibliometric analysis; chemotherapeutic resistance; citespace; lncRNA
Year: 2019 PMID: 31143372 PMCID: PMC6524938 DOI: 10.18632/oncotarget.26938
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Publication outputs and growth prediction.
The number of publications from 2008 to 2017 represented by the solid line; the dashed line represents the forecast curve, R2 = 0.9873.
The top active 15 journals that published these publications
| Ranking | Journal | Country | Count | Percentage (%) | IF2017 |
|---|---|---|---|---|---|
| 1 | Oncotarget | United States | 60 | 11.364 | 5.168 |
| 2 | Oncology Reports | United States | 15 | 2.841 | 2.976 |
| 3 | Tumor Biology | Switzerland | 15 | 2.841 | 3.27 |
| 4 | Cellular Physiology and Biochemistry | Switzerland | 12 | 2.273 | 5.500 |
| 5 | International Journal of Molecular Sciences | United States | 12 | 2.273 | 3.687 |
| 6 | Biomedicine and Pharmacotherapy | France | 11 | 2.083 | 3.457 |
| 7 | PLOS ONE | United States | 11 | 2.083 | 2.766 |
| 8 | Cell Death and Disease | England | 10 | 1.894 | 5.638 |
| 9 | Molecular Cancer | England | 10 | 1.894 | 7.776 |
| 10 | Oncology Letters | Greece | 9 | 1.705 | 1.664 |
| 11 | OncoTargets and Therapy | England | 9 | 1.705 | 2.656 |
| 12 | Biochemical and Biophysical Research Communications | United States | 8 | 1.515 | 2.559 |
| 13 | Cancer Chemotherapy and Pharmacology | United States | 8 | 1.515 | 2.808 |
| 14 | Cancer Letters | Netherlands | 8 | 1.515 | 6.491 |
| 15 | International Journal of Clinical and Experimental Medicine | United States | 8 | 1.515 | 0.833 |
Figure 2Dual-map overlay of journals on lncRNA and chemoresistance.
Citation paths at a disciplinary level were demonstrated in t a dual-map overlay. The left of the map represented the cite journals and the right of the map represented the cited journals. Citation trajectories are colored based on the citing regions. The width of the paths is proportional to the z-score-scaled citation frequency.
Figure 3The distribution of countries/territories and institutions.
(A) Map of countries/territories that published these publications. (B) Map of institutions that published these publications.
The top ten productive countries and institutions of the total publications
| Ranking | Country | Count | Institution | Count |
|---|---|---|---|---|
| 1 | China | 358 | Nanjing Medical University | 29 |
| 2 | USA | 98 | Zhengzhou University | 22 |
| 3 | Italy | 21 | Central South University | 21 |
| 4 | Germany | 17 | Shanghai Jiao Tong University | 21 |
| 5 | England | 14 | China Medical University | 20 |
| 6 | Australia | 9 | Nanjing University | 14 |
| 7 | Japan | 9 | Tongji University | 13 |
| 8 | Taiwan | 9 | Dalian Medical University | 13 |
| 9 | Canada | 6 | Harbin Medical University | 11 |
| 10 | Iran | 6 | University Texas MD Aanderson Cancer Center | 10 |
The top 10 authors and co-cited authors working in the field
| Ranking | Author | Count | Co-cited Author | Count |
|---|---|---|---|---|
| 1 | Wang Y | 13 | Gupta RA | 87 |
| 2 | Li J | 11 | Wang Y | 79 |
| 3 | Liu Y | 11 | Mercer TR | 58 |
| 4 | Li X | 9 | Gutschner T | 55 |
| 5 | Wang J | 8 | Fan Y | 51 |
| 6 | Wang L | 7 | Wang F | 48 |
| 7 | Li L | 7 | Tsang WP | 47 |
| 8 | Li Y | 7 | Wang KC | 46 |
| 9 | Zhang L | 7 | Li J | 43 |
| 10 | Shang C | 6 | Jemal A | 38 |
Figure 4The analysis of references.
(A) Co-citation knowledge map of references on lncRNA and chemoresistance. (B) Timeline view of references on lncRNA and chemoresistance with log-likelihood ratio (LLR) cluster labels. The color of the node represents the newness of the related reference (the red color for new studies).
Figure 5The top 9 keywords with the strongest citation bursts.